LBRX Stock Analysis: LB Pharmaceuticals Common | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.204m USD | 12M Return: 143.1% | US50180M1080 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 13.6M
Qual. Beats: -1
Warnings
Tailwinds
Seasonality 1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
LB Pharmaceuticals Inc (NASDAQ: LBRX) is a clinical-stage biopharmaceutical company headquartered in New York, NY, founded in 2015. The company is focused on developing therapies for neuropsychiatric conditions, with its lead candidate LB-102, an oral small molecule, advancing through multiple clinical programs. LB-102 is currently in Phase 3 trials for acute schizophrenia, has completed Phase 2 for bipolar I depression, is being studied as adjunctive treatment for major depressive disorder (MDD), and is in pre-clinical development as a long-acting injectable (LAI) formulation. As a clinical-stage company, LB Pharmaceuticals has not yet commercialized a product and depends on capital markets to fund its research and development pipeline. The company completed its IPO on September 11, 2025, and operates in the pharmaceuticals sub-industry within the broader health care sector, an area characterized by high unmet medical need and lengthy development timelines.
- Phase 3 schizophrenia data for LB-102 approaches readout
- Pipeline expands into bipolar depression and MDD indications
- Cash burn rate signals potential dilutive share offering
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.23 > 0.02 and ΔFCF/TA 196.0 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.23 > 3% & CFO -82.4m > Net Income -85.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 15.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (30.1m) vs 12m ago 11.9k% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.92 (Total Current Assets 355.3m - Total Current Liabilities 23.6m) / Total Assets 361.7m |
| B: -0.55 (Retained Earnings -200.2m / Total Assets 361.7m) |
| C: -0.46 (EBIT TTM -88.0m / Avg Total Assets 190.5m) |
| D: 11.33 (Book Value of Equity 332.3m / Total Liabilities 29.3m) |
| Altman-Z'' = 13.00 = AAA |
As of October 01, 2026, the stock is trading at USD 38.38 with a total of 437,200 shares traded. Over the past week, the price has changed by -2.07%, over one month by -18.79%, over three months by +18.26% and over the past year by +143.07%.
Current recommended Stop Loss: 35.70 (which is 7% or 1.3 ATR below the current price).
LB Pharmaceuticals Common has no consensus analysts rating.
P/B = 4.1408
Revenue TTM = 0.0 USD
EBIT TTM = -88.0m USD
EBITDA TTM = -87.7m USD
Long Term Debt = 4.37m USD (estimated: total debt 5.22m - short term 844k)
Short Term Debt = 844k USD (from shortTermDebt, last quarter)
Debt = 5.22m USD (from shortLongTermDebtTotal, last quarter) (leases 5.22m already included)
Net Debt = -322.6m USD (calculated: Debt 5.22m - CCE 327.8m)
Enterprise Value = 881.7m USD (1.20b + Debt 5.22m - CCE 327.8m)
Interest Coverage Ratio = unknown (Ebit TTM -88.0m / Interest Expense TTM 0.0)
EV/FCF = -10.64x (Enterprise Value 881.7m / FCF TTM -82.8m)
FCF Yield = -9.39% (FCF TTM -82.8m / Enterprise Value 881.7m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 345k) / Revenue TTM)
Tobins Q-Ratio = 2.44 (Enterprise Value 881.7m / Total Assets 361.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 5.22m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -69.5m (EBIT -88.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 15.08 (Total Current Assets 355.3m / Total Current Liabilities 23.6m)
Debt / Equity = 0.02 (Debt 5.22m / totalStockholderEquity, last quarter 332.3m)
Debt / EBITDA = 3.68 (negative EBITDA) (Net Debt -322.6m / EBITDA -87.7m)
Debt / FCF = 3.89 (negative FCF - burning cash) (Net Debt -322.6m / FCF TTM -82.8m)
Total Stockholder Equity = 330.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.99% (Net Income -85.7m / Total Assets 361.7m)
RoE = -25.91% (Net Income TTM -85.7m / Total Stockholder Equity 330.6m)
RoCE = -26.27% (EBIT -88.0m / Capital Employed (Equity 330.6m + L.T.Debt 4.37m))
RoIC = -20.51% (negative operating profit) (NOPAT -69.5m / Invested Capital 339.0m)
WACC = 9.62% (E(1.20b)/V(1.21b) * Re(9.66%) + D(5.22m)/V(1.21b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 63.75 | Cagr: 159.0%
[DCF] Fair Price = unknown (Cash Flow -82.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.31 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=-1.56 | Chg30d=-68.17% | Revisions=-62% | Analysts=5
EPS current Year (2026-12-31): EPS=-5.54 | Chg30d=+0.26% | Revisions=-67% | GrowthEPS=-77.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-5.04 | Chg30d=-1.76% | Revisions=-44% | GrowthEPS=+9.1% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -75% (up=1, down=16)